Since my earlier article, Neurocrine Biosciences (NBIX) shares have retreated quite a bit off all time highs in September 2018. The safety scare was the first major selloff on elevated volume as an increase in reported deaths caused a panic, sending shares down over 10% one day in November. The second major selloff was a product of the failed T-Force GOLD trial for the once coveted Tourette's indication, sending shares down over 21% to erase nearly $1.5 billion in market capitalization. This reaction seemed overdone for an indication that had already proved